Page last updated: 2024-12-05

tuaminoheptane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tuaminoheptane: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5603
CHEMBL ID123693
CHEBI ID134753
SCHEMBL ID37510
MeSH IDM0179791

Synonyms (101)

Synonym
AKOS009031171
(+)-2-aminoheptane
nsc27160
nsc-27160
DIVK1C_000267
KBIO1_000267
SPECTRUM_000548
tuaminheptanum
tuaminoheptanum [inn-latin]
dl-2-aminoheptan
brn 0635676
tuaminoheptano [inn-spanish]
einecs 204-655-5
ai3-16557
(rs)-2-heptylamin
heptamine (sympathomimetic)
nsc 1091
BSPBIO_002940
NCGC00178382-01
tuaminoheptane (inn)
D07371
SPECTRUM5_001517
heptamine
heptamine, sympathomimetic
rineptyl
1-methylhexylamine
armeen l-7
tuaminoheptane
rineptil
hexylamine, 1-methyl-
tuaminoheptan
2-heptanamine
nsc-1091
methyl-n-hexylamine
heptedrine
heptin
wln: zy5 & 1
2-aminoheptane
2-heptylamine
tuamine
nsc1091
dl-2-aminoheptane
123-82-0
2-aminoheptane, 99%
IDI1_000267
KBIOSS_001028
KBIO2_001028
KBIOGR_000875
KBIO2_003596
KBIO2_006164
KBIO3_002160
SPECTRUM3_001380
SPECTRUM2_000547
NINDS_000267
SPBIO_000593
SPECTRUM4_000378
CHEBI:134753
CHEMBL123693
inchi=1/c7h17n/c1-3-4-5-6-7(2)8/h7h,3-6,8h2,1-2h3
vsrbkqfnfzqrbm-uhfffaoysa-
H0645
heptan-2-amine
S4520
tuaminoheptanum
tuaminoheptane [usp:inn:ban]
unii-z0420gyd84
3-04-00-00374 (beilstein handbook reference)
tuaminoheptano
z0420gyd84 ,
BP-10641
FT-0605250
FT-0605043
tuaminoheptane [who-dd]
tuaminoheptane [inn]
tuaminoheptane [mi]
SCHEMBL37510
1-methyl-hexylamine
DTXSID6048468
1-methylhexylamine #
HY-B0952
AB00053564_02
STL453605
sec-heptanamine
J-004986
tuaminoheptanez
(?)-2-aminoheptane
mfcd00008101
SBI-0051550.P002
F0001-0370
Q4000097
DB13238
sodiumhexafluoroarsenate(v)
HMS3885L06
AMY3809
CCG-266064
D90921
2-amino-heptane
AS-56444
tuaminoheptane 100 microg/ml in acetonitrile
EN300-21292
Z104495176

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"7-fold I(VRAC) and reduced the inhibition of VRAC by heptylamine with a dose-response curve shifted approximately 10-fold to the right."( The amine-containing cutaneous irritant heptylamine inhibits the volume-regulated anion channel and mobilizes intracellular calcium in normal human epidermal keratinocytes.
Colomban, C; Crest, M; Delmas, P; Raoux, M, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
alkylamineAny primary amine in which the substituent attached to nitrogen is an alkyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mu-type opioid receptorHomo sapiens (human)IC50 (µMol)0.01400.00010.813310.0000AID152061
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID152061Antagonistic activity towards Opioid receptor mu 11999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Mixture-based synthetic combinatorial libraries.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (50.00)18.7374
1990's3 (15.00)18.2507
2000's2 (10.00)29.6817
2010's5 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.24 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.70 (4.65)
Search Engine Demand Index70.16 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (48.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (95.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]